Oral chemotherapy in cancers: what about adherence?  by Tanz, Rachid et al.
letters
Hematol Oncol Stem Cell Ther 5(3)     Third Quarter 2012 hemoncstem.edmgr.com170
Oral chemotherapy in can-
cers: what about adher-
ence?
To the Editor: Oral chemothera-
py is a convenient treatment option, 
allowing spacing hospitalizations 
and avoiding complications of cen-
tral venous access; however, oral 
administration raises the problem 
of adherence, which may compro-
mise effectiveness by not following 
the proper administration schedule 
from underdosing or increasing the 
risk of toxicity from overdosing. 
We conducted this retrospective 
case-control study at the National 
Institute of Oncology in Rabat, 
from 2008 to 2010, to evaluate 
factors influencing adherence to 
oral chemotherapy. All patients 
treated with capecitabine for breast 
or digestive cancer for at least six 
months were included (Table 1). 
Nonadherence was defined as tak-
ing less than 90% or more than 
110% of the daily dose, missing 
more than two doses per cycle or not 
following the administration sched-
ule with an interval between daily 
doses of less than 8 or more than 12 
hours. SPSS version 17 was used 
for statistical tests with a P value 
<.05 considered significant. Good 
adherence was observed in 56.3% 
of patients (Table 2). Patients with 
poor adherence were significantly 
older, had a lower educational level, 
and were taking more other chronic 
medications compared with the rest 
of our sample. Sex, cancer type and 
stage had no significant influence on 
adherence (Table 3).
Nonadherence to oral chemo-
therapy may lead to toxicity, thera-
peutic resistance and tumor pro-
gression. The few studies that have 
addressed the issue indicate the 
magnitude of the problem. Poor 
adherence to tamoxifen was associ-
ated with an increased risk of death 
in breast cancer in one study.1 In 
another, adherence to oral cyclo-
phosphamide was only 57% in a 
breast cancer study.2 In 108 patients 
with hematologic malignancies, the 
adherence rate was 27% for predni-
sone and only 17% for allopurinol.3 
In a large study involving 2378 pa-
tients receiving adjuvant tamoxifen 
for breast cancer, adherence was 
87% during the first year, but only 
50% after 4 years.4 
Good adherence depends on 
several factors, including the com-
plexity of the medication regimen, 
side effects, and limited access to 
drugs.5 Patients may have a limited 
understanding of the goals of ther-
apy. Patient education is extremely 
important to therapeutic results 
and possible side effects. Poor com-
munication with the medical team 
is often correlated with poor adher-
ence.6 In a study involving 384 pa-
tients treated for chronic diseases, 
including cancers, an understand-
ing of the need for treatment was 
a more powerful factor for greater 
adherence than clinical signs or so-
cioeconomic level. Apprehension 
over side effects, as in our study, was 
correlated with lower adherence 
rates.7 Patients with poor compli-
ance to capecitabine were older than 
the rest of our sample. In a general 
population, factors associated with 
nonadherence to oral chemotherapy 
were low socioeconomic level, insti-
tutionalization, and the daily dos-
age of treatment.8 Elderly patients 
may also have cognitive impairment 
(even minor) and are often under-
diagnosed. They often have chronic 
conditions requiring long courses 
of treatment that can be confusing 
in combination with oral chemo-
therapy. In an ambulatory elderly 
population, Darnell et al found a 
compliance rate of 78% for a single 
long-term medication, 54% for 
three medications and only 21% for 
six concomitant medications.9 
Good adherence to capecitabine 
for patients with t(9;11) remained 
significantly longer even when only 
patients treated with HSCT in first 
remission were considered (Figure 
3), although numbers were small. 
All five patients with t(9;11) were 
treated with HSCT in CR1.
The data supports the conclu-
sion that MLL-positive t(9;11) 
AML patients should be classi-
fied differently from the rest of the 
MLL-rearranged cases and should 
be considered as part of the inter-
mediate-risk group. This classifica-
tion separating the t(9;11) cases 
from the rest of the MLL-positive 
cases should be maintained even 
when patients are treated with al-
logeneic HSCT. 
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was related to educational level in 
our study. Davies et al found that 
the effect of educational level on 
adherence to a twice-daily adminis-
trated drug was 80.2%, 62.8% and 
34.7% for an education level consid-
ered normal, intermediate and low, 
respectively.10 Educational level ap-
pears to be the key factor for good 
adherence to oral chemotherapy. 
The training of health profes-
sionals required is not yet a stan-
dard. A large study in United States 
conducted in 42 cancer centers 
showed that only one-third of care-
givers involved in management of 
patients on oral chemotherapy had 
received specific training.11 Kav et 
al showed that 47% of more than 
1000 oncology nurses never had 
specialized training and only 27% 
considered themselves able to re-
spond to various questions from 
patients on oral chemotherapy.12 
Further efforts are needed to im-
prove this situation. 
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Table 1. epidemiological characteristics of 103 patients.
Characteristics N Percentage
age (mean, Sd) 51.4 years (12.1)
Sex
   Women 49 47.6
   Men 54 52.4
Level of education
   analphabet 41 39.8
   primary 17 16.5
   Secondary 41 39.8
   University 4 3.9
pathology
   breast 69 67
   digestive 34 33
Stage
   Localized 20 19.4
   Metastatic 83 80.6
Table 2. Type of nonobservance.
Characteristics  n Percentage
doses 31 30.1
Underdosing 28 27.2
Overdosing 3 2.9
number taking 14 13.6
Timing 16 15.5
Table 3.  nonadherence factors.
Factors Adherent patients Non-adherent patients P
average age 47.6 55.6 .002
Low instruction 
level 41% 62% .01
polymedication 26.6% 43.3 .04
